Induction of hypogonadism is standard-of-care for advanced prostate cancer. Gonadotropic releasing hormone (GnRH) agonists and antagonists lower testosterone with similar efficacy but may be associated with increased cardiovascular risk. In small randomized controlled trials (RCTs) comparing the two, one found no difference, whereas another and a non-randomized study found a difference among individuals with cardiac comorbidities.[1-3], Given this discrepancy, and with cardiovascular disease the most common cause of non-cancer death in prostate cancer patients,[4] we compared reporting of cardiac events in patients treated with GnRH agonists and antagonists using disproportionality analysis.
BJU international. 2020 Mar 30 [Epub ahead of print]
Eugene B Cone, Maya Marchese, Stephen Reese, Maxine Sun, Junaid Nabi, Kerry Kilbridge, Quoc-Dien Trinh
Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.